Abstract:Background: Loss of cyclooxygenase-2 activity is known to impair fracture-healing in animal models and to inhibit heterotopic ossification in humans. Cyclooxygenase-2 is the rate-limiting enzyme involved in the conversion of arachidonic acid into prostaglandins. Arachidonic acid also is a substrate for 5-lipoxygenase, which catalyzes the initial steps in leukotriene synthesis. In contrast to cyclooxygenase-2, genetic ablation of 5-lipoxygenase accelerates and enhances fracture-healing in mice. The goal of this study was to determine if systemic inhibition of 5-lipoxygenase with an orally delivered drug could accelerate fracture-healing. Methods: Closed femoral fractures were made in Sprague-Dawley rats. The rats were treated with oral doses of vehicle (ninety-five rats), celecoxib (fifty-nine rats), or AA-861 (a 5-lipoxygenase inhibitor; eighty-nine rats). Fracture-healing was measured with use of radiographs, histomorphometry, and biomechanical testing. Effects of drug treatments on callus cell proliferation and gene expression were determined by incorporation of bromodeoxyuridine and quantitative polymerase chain reactions, respectively. Results: AA-861 treatment decreased fracture-bridging time, significantly increased early callus cartilage (5.6-fold; p < 0.001) and bone formation (4.2-fold; p = 0.015), and significantly increased callus mechanical properties compared with the vehicle-treated rat fractures. Callus cell proliferation rate was increased by AA-861 treatment, compared with vehicle, at day 2 after fracture (3.68% compared with 2.08%; p < 0.001; 95% confidence interval, -2.81 to -0.039) but was reduced by celecoxib treatment at day 4 after fracture (4.22% compared with 1.84%; p < 0.001; 95% confidence interval, 2.27 to 4.07). At day 10 after fracture, AA-861 and celecoxib treatment increased Type-II collagen mRNA levels (16.0-fold and 6.1-fold, respectively; p < 0.001 for both), but only AA-861 treatment caused an increase in Type-X collagen mRNA (6.3-fold; p < 0.001). AA-861 treatment significantly increased cyclooxygenase-2 (4.0-fold at day 10; p < 0.001) and osteopontin mRNA levels (3.6-fold at day 7; p = 0.024), while decreasing 5-lipoxygenase mRNA levels (5.6-fold at day 4; p < 0.001). Conclusions: Systemic inhibition of 5-lipoxygenase with an orally delivered drug significantly accelerated and enhanced fracture-healing in this rat model. Gene expression analysis indicates that cyclooxygenase-2 is necessary for callus chondrocytes to progress into hypertrophy so as to complete endochondral ossification. Conversely, inhibition of 5-lipoxygenase alters the inflammatory response, which enhances callus chondrocyte hypertrophy and accelerates endochondral ossification.

Effects of a selective cyclooxygenase-2 inhibitor (celecoxib) on fracture healing in rats

A Comparison Between the Effects of Acetaminophen and Celecoxib on Bone Fracture Healing in Rats

Effect of celecoxib on hepatic and renal functions in rats with mammary carcinoma

Short-Term Celecoxib Promotes Bone Formation without Compromising Cefazolin Efficacy in an Early Orthopaedic Device-Related Infection: Evidence from a Rat Model

Effects of celecoxib on bone in SD rats

Short-term administration of non-selective and selective cox-2 nsaids do not interfere with bone repair in rats

Celecoxib in the Histological Grade of Chemically Induced Mammary Tumor in Rats

Parecoxib has non-significant long-term effects on bone healing in rats when administered for a short period after fracture

Selective COX-2 inhibitor reduces bone healing in bone defects

Controlled release of celecoxib inhibits inflammation, bone cysts and osteophyte formation in a preclinical model of osteoarthritis

Pharmacological inhibition of 5-lipoxygenase accelerates and enhances fracture-healing

Effects of Glucocorticoids on Fracture Healing in Rats

The Selective Cyclooxygenase-2 Inhibitor Celecoxib Reduces Bone Resorption, but Not Bone Formation, in Ovariectomized Mice in Vivo

Low-level laser therapy improves bone repair in rats treated with anti-inflammatory drugs

Cross-species comparisons reveal resistance of human skeletal stem cells to inhibition by non-steroidal anti-inflammatory drugs

Cellular and molecular mechanisms of accelerated fracture healing by COX2 gene therapy: studies in a mouse model of multiple fractures.

Effect of continuous dynamic pressure stress on cyclooxygenase mRNA expression,bone mass and mechanical properties during fracture healing process in rabbits

Inhibitory Effect of Celecoxib on Titanium Particle-Induced Osteoclastogenesis Through Inactivation of Cyclooxygenase-2

Selective Cyclooxygenase-2 Inhibitor Restrains Titanium-Particle-induced Inflammatory Osteolysis by Regulating RANK/RANKL Signaling Pathway

Evaluation of the Anti-Inflammatory and Chondroprotective Effect of Celecoxib on Cartilage Ex Vivo and in a Rat Osteoarthritis Model

Defective bone repair in diclofenac treated C57Bl6 mice with and without lipopolysaccharide induced systemic inflammation